Clinical Trial Update: Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone

View source ↗

Summary

A completed real-world study in Taiwan assessing the safety profile and how Radium-223 dichloride behaves in routine clinical practice for castration-resistant …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Radium-223 dichloride (radium-223 dichloride)

Snippet

Sponsor: Bayer | Conditions: Castration-resistant Prostate Cancer | Status: COMPLETED